Cancer Vaccines and Immunotherapy

National Institute Of Allergy And Infectious Diseases

Investigators

Abstract

1. Developed a new concept termed ACT-VaxInnate. This focused on generating stem like T cells for ACT therapy using small molecule inhibitors of specific intracellular T cell pathways to improve the quality of the response. These small molecule inhibitors are approved drugs for other cancer indications so could be readily tested in humans to optimize T cells for ACT. 2. Demonstrated that tumor control is optimal when ACT is followed by vaccination to expand the T cells transferred by ACT and provide innate stimulation to alter the tumor microenvironment. 3. Developed spatial transcriptomics to provide the first in vivo analysis for how ACT mediates protection against a tumor model.